The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|March 29, 2018
Treatment of NSCLC With Uncommon EGFR Mutations
Treatment of NSCLC With Uncommon EGFR Mutations
Advertisement
- A female patient, Chinese descent, aged 66, is referred from primary care with persistent cough, sputum with blood, shortness of breath and chest pain
- History
- Never smoked
- Recurrent bronchitis over past 5 years
- Has never been screened for lung cancer (by radiography or low-dose CT [LDCT])
- Hypertension controlled on HCTZ; no diabetes, renal impairment
- Family history
- Grew up in China, moved to US at age 29; married for 30 years
- Grew up in family with heavy smokers
- Husband is current smoker
- LDCT reveals multiple tumors in left lung with pleural metastases
- Biopsy reveals non-small cell lung cancer
- Molecular analysis:
- EGFRmutation: G719X
- Negative forALKrearrangement
- Wild-typeKRAS
- The patient was started on afatinib, 40 mg once daily
- After one month on therapy, she reported having rather severe diarrhea (5 times/day)
- Treatment was discontinued, then re-started treatment at 30 mg/day
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
5